| Line 169: | Line 169: | ||
*Acknowledgement: This study was conducted while the first author was at Medical University of Silesia, Poland and was supported by the Ministry of Science and Higher Education of Poland under grant number N N404 025638. Analysis of nitrosamines at the University of California, San Francisco was supported by grants P30 DA012393 and S10 RR026437 from the National Institutes of Health. | *Acknowledgement: This study was conducted while the first author was at Medical University of Silesia, Poland and was supported by the Ministry of Science and Higher Education of Poland under grant number N N404 025638. Analysis of nitrosamines at the University of California, San Francisco was supported by grants P30 DA012393 and S10 RR026437 from the National Institutes of Health. | ||
===2014: Evaluation of Toxicant and Carcinogen Metabolites in the Urine of E-Cigarette Users Versus Cigarette Smokers=== | ===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481723/ Evaluation of Toxicant and Carcinogen Metabolites in the Urine of E-Cigarette Users Versus Cigarette Smokers]=== | ||
*With respect to the compounds analyzed here, e-cigarettes have a more favorable toxicity profile than tobacco cigarettes. | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481723/pdf/ntu218.pdf PDF Version] | |||
*Citation: Hecht SS, Carmella SG, Kotandeniya D, Pillsbury ME, Chen M, Ransom BW, Vogel RI, Thompson E, Murphy SE, Hatsukami DK. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res. 2015 Jun;17(6):704-9. doi: 10.1093/ntr/ntu218. Epub 2014 Oct 21. PMID: 25335945; PMCID: PMC4481723. | |||
*Acknowledgement: This work was supported by the National Cancer Institute at the National Institutes of Health (R01 CA081301, U19 CA157345, and CA77598). | |||
<br> | <br> | ||
edits